Navigation Links
VCU Massey Cancer Center to partner with Israeli biotech firm
Date:3/25/2008

The Virginia Commonwealth University Massey Cancer Center will open a Phase I pancreatic cancer study later this year in conjunction with leading researchers from Israel, marking the first time cancer researchers at VCU have partnered with their counterparts in Israel.

The study is supported by a $950,000 grant from the U.S.-Israel Bi-National Industrial Research and Development Foundation (BIRDF). Leaders from the Virginia Israel Bioscience Commercialization Center (VIBCC) helped to foster Israeli interest in research at VCU.

The clinical trial, designed by Massey principal investigator Ray Lee, M.D., Ph.D., involves a novel targeted therapeutic agent developed by BioCancell of Jerusalem and will offer new hope for one of the most difficult-to-treat cancers.

This collaboration is a tangible outcome of the initiative launched by the Virginia BioTechnology Research Park more than a year ago to recruit Israeli life science companies with innovative products and technologies to Virginia and the Research Park, said Robert T. Skunda, President and CEO of the research park.

The world, indeed, is getting flatter, said Donna Edmonds, executive director of the Virginia Israel Bioscience Commercialization Center. By importing and exporting high-quality medical research and building collaborative clinical studies such as this, we can work toward saving more lives of people with cancer in Virginia and across the globe.

Gordon D. Ginder, M.D., director of the VCU Massey Cancer Center, said, Having an organization dedicated to promoting Virginias academic, clinical and biotechnological expertise is a boon to the Commonwealth. As federal funding for cancer research in the United States has shrunken in the face of expanding scientific opportunities for better treatment and prevention, its vital that we explore international collaborations and funding sources, too. We are grateful to the VIBCC for serving as a beacon to guide international funding and research opportunities to us.

About Pancreatic Cancer

About 30,000 people die from pancreatic cancer each year. It has a high mortality rate and ranks as the fourth leading cause of cancer-related death as its symptoms often do not present until the disease is in a late stage. Fewer than 5 percent of patients survive for more than five years, giving pancreatic cancer the lowest survival rate of any common cancer type.

Currently the best treatment option for pancreatic cancer is through high-risk surgical removal of part of the pancreas. However, if the cancer affects surrounding vessels and lymph nodes, surgery often is not an option. Chemotherapy and radiation provide alternative treatment options, however, the median survival rate on those protocols is just one year.

About the Clinical Trial

This study involves a novel, gene-based therapy for pancreatic cancer developed by BioCancell. Its new therapeutic agent links a DNA fragment that is responsible for tumor-specific expression of a gene, with a suicidal toxin gene. When the agent is injected directly into the tumor, the DNA fragment will induce the expression of the suicidal toxin in the cancer cells but not in normal tissue. The researchers expect to avoid damaging normal tissue while killing tumor cells.

Candidates for the study are adults with locally advanced pancreatic cancer who are not candidates for immediate surgical resection. Researchers will inject the new agent into cancer directly through a laparoscopic procedure.

Using this approach in pancreatic cancer, they hope that tumors could be down-staged from unresectable status, or inoperable, to resectable, giving patients a better chance of remission.

This agent has been tested and shown to be effective in animal models and anecdotally in two metastatic cancer patients in Israel. The liver lesions of those two patients showed success in shrinkage.

Beginning in the summer of 2008, Massey expects to begin enrolling patients. Lee is the principal investigator, and Brian Kaplan, M.D., a surgical oncologist at Massey, will be the co-principal investigator performing the laparoscopic surgery. Abraham Czerniak, M.D., Ph.D., of Sheba Medical Center, Ramat Gan, Israel, will be responsible for the Israeli arm of the study, which expects to enroll one-third of the total patient base.


'/>"/>

Contact: Andrea Butler
albutler@vcu.edu
804-628-2111
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Targeting aggressive breast cancers by putting them to sleep
2. MRI findings help forecast prostate cancer prognosis
3. Radiologists use special MRI to identify brain cancer early
4. Womans Abdominal Organs Removed in Unique Cancer Surgery
5. OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
6. Many Phase 3 Cancer Drug Trials Yield Effective Medicines
7. Cancer treatments in phase 3 trials successful up to half of the time
8. African Americans less likely than whites to get colonoscopy despite family history of colon cancer
9. Obesity may keep some women from getting screened for breast, cervical cancer
10. WellPoints Health Plans to Cover Newly Approved Cancer Treatment
11. Obese Women Less Likely to Be Tested for Some Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... S.S. Nesbitt as the latest addition to its growing list of Partner Firms. ... throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing the ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... Florida (PRWEB) , ... February 10, 2016 , ... ... Club) announced that it has been awarded the prestigious Distinguished Emerald Club of ... award program conducted by BoardRoom magazine, one of the most respected trade publications ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Workrite Ergonomics ... most versatile series of monitor mounts ever. , “Our goal was to develop ... easy to install system that we have ever created.” said Darren Hulsey, Product Manager ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, ... Monday night, Feb. 8, prior to the evening session of the university’s 80th Annual ... GO! Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 --> --> ... Japan .  --> Japan .  --> A ... With submission, Shire continues to strengthen ... With submission, Shire continues to strengthen its presence ... submission, Shire continues to strengthen its presence ...
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology: